Dr. Luiz Miguel Camargo is a Senior Commercialization Advisor, where he helps translate cutting-edge government-funded research into the commercial sector, with a strong focus on pharmaceutical and biotech innovation.

Miguel has more than 20 years of experience in drug discovery, much of it driven by applying data science to real-world translational challenges. He has led innovative data efforts at Merck, Novartis, and UCB, working across translational medicine, target and biomarker discovery, lead identification and optimization, phenotypic screening, and disease definition using electronic medical records. In addition to his role as a computational biologist, Miguel has directed multidisciplinary drug discovery teams and led academic and industrial collaborations. At UCB, he was responsible for expanding the company’s U.S. research presence through building and acquiring cutting-edge discovery platforms, and for developing its Targeted Protein Degradation Platform, spanning research hubs in Belgium, the UK, and the U.S.

Beyond his corporate leadership roles, Miguel is the founder and advisor of multiple start-ups in protein editing, active immunity for oncology, genetics of founder populations, emergency care at the point of care, and privacy-preserving computation on encrypted data. He also served as a Senior Commercialization Advisor at In-Q-Tel, and now NobleReach, where he worked on translating emerging technologies and commercializing several DARPA- and NSF-funded projects. In addition, he continues to act as an advisor to a major pharmaceutical company and a venture fund, supporting strategic decision-making at the intersection of science, technology, and commercialization.

Miguel received his PhD in bioinformatics from the University of Cambridge and has authored numerous publications in leading scientific journals. He serves on the Board of Trustees of the Cambridge School of Weston in Massachusetts. He lives in Wellesley, MA, with his family.